# INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders

> **NCT01788072** · PHASE2 · COMPLETED · sponsor: **Holland Bloorview Kids Rehabilitation Hospital** · enrollment: 70 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Intranasal Oxytocin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01788072
- **Lead sponsor:** Holland Bloorview Kids Rehabilitation Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2017-08
- **Final completion:** 2017-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01788072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01788072, "INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01788072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*